胶质瘤组织中整合素β_1及Ki-67表达的临床意义

Clinical significance of integrin β_1 and Ki-67 expressions in gliomas

目的:探讨胶质瘤中整合素β1及Ki67的表达及其临床意义。方法:应用免疫组化方法检测45例胶质瘤、5例正常脑组织中整合素β1及Ki67的表达。结果:在Ⅰ、Ⅱ级和Ⅲ、Ⅳ级胶质瘤中,整合素β1的阳性表达率分别为42.11%(8/19)及73.08%(19/26),差异有统计学意义,χ2=4.388,P=0.036;Ki67标记指数分别为(7.06±4.17)%和(13.45±8.69)%,差异有统计学意义,t=3.269,P=0.002;且整合素β1的表达与Ki67标记指数具有正相关关系,r=0.71,P=0.000。结论:整合素β1表达上调能促进胶质瘤细胞的增殖及侵袭;整合素β1与Ki67的表达均可应用于临床,作为评价胶质瘤恶性程度、选择治疗措施及预测患者预后等的重要指标。

OBJECTIVE： To investigate the expressions of integrin β1 and Ki 67 antigens in gliomas and their clinical significance. METHODS： The immunohistochemical assay was used to determine the expressions of integrin β1 and Ki 67 antigens in gliomas （45 cases） and normal brain tissues （5 cases）. RESULTS： In gliomas of grade Ⅰ - Ⅱ and grade Ⅲ - Ⅳ, the positive expression rates of integrin β1 were 42. 11%（8/19）and 73.08%（19/26）, respectively, x^2= 4. 388. P=0. 036; the Ki 67 labeling indexes were （7.06±4. 17）% and （13.45 ±8.69）%, respectively, t=3.269, P=0.002. The differences were statistical significance. Moreover, there was a posirive correlation between the expression of integrin β1 and Ki 67 labeling index, r= 0.71, P=0. 000. RESULTS： The up-regulating expression of integrin β1 in gliomas promotes proliferation and invasion of glioma cells. The expressions of integrin β1 and Ki-67 can be applied as a cogent indicator clinically to judge the malignant grade of human gliomas, to select treatment strategies, and to predict prognoses of the patients.